Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 1 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the six months ended 30 June 2014, SkyePharma PLC revenues increased 10% to L34.4M. Net loss increased from L1.7M to L17.7M. Revenues reflect Revenue increase of 10% to L23.9M, Other Revenue increase from L800K to L2.1M. Higher net loss reflects Loss on Extinguishment of bonds increase from L0K to L25.1M (expense), Foreign exchange gain on net debt decrease from L600K (income) to L500K (expense). more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
D+
D+

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: N/A Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
3 brokers Broker Consensus Trend
Broker Recommendations for SkyePharma
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Edison Investment Research Franc Gregori , N+1 Singer Jens Lindqvist Sheena Berry ,

SkyePharma PLC is a pharmaceutical company. The Company validates drug delivery technologies to develop oral and inhalation pharmaceutical products. The Company operates in United Kingdom, Rest of Europe, North America and Rest of world. The principal activities of the Company included the research and development, manufacture and sale of prescription pharmaceutical products. The Company is engaged in the development and manufacture of pharmaceutical products based on information used internally by management to assess the performance of, and allocate resources to the business. The Company’s subsidiaries include SkyePharma Production SAS, SkyePharma (Jersey) Limited, Jago Holding AG, Jagotec AG, SkyePharma AG, SkyePharma Holding AG and SkyePharma Holding Inc.

Directors: Peter Grant (CEO) 58, Andrew Derodra (CFO) 47, John Murphy (GCN) 60, Frank Condella (NEC) 59, John Biles (NED) 66, Jean-Charles Tschudin (NID) 71, Thomas Werner (NID) 57,

No. of Employees: 79 No. of Shareholders: 0


Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 104,812,259
Free Float 103.0m (98.3%)
ISIN GB00B3BFNB64

SKP Share Price Performance SKP Quote
369p
16.5  4.7%
Traded 5:46pm · Minimum 15 min delayed · NMS: 1.50k

Latest SKP News Announcements (delayed)

Upcoming SKP Events
No upcoming events.
Recent ↓
Tuesday 1st April, 2014
SkyePharma PLC Secondary Public Offering Filing
Monday 31st March, 2014
Full Year 2013 SkyePharma PLC Earnings Presentation
Monday 31st March, 2014
Full Year 2013 SkyePharma PLC Earnings Release
Tuesday 11th March, 2014
SkyePharma PLC at EBD BIO-Europe Spring
Friday 31st January, 2014
SkyePharma PLC Trading Update
Wednesday 4th December, 2013
SkyePharma PLC Capital Markets Meeting
Tuesday 5th November, 2013
SkyePharma PLC at EBD Group BIO-Europe
Thursday 10th October, 2013
SkyePharma PLC Interim Management Statement for the period 1 July 2013 to 9 October 2013
Friday 20th September, 2013
SkyePharma PLC Capital Markets Day - Morning Session
Friday 20th September, 2013
SkyePharma PLC Capital Markets Day - Afternoon Session


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy SKP

Access SKP Analytics Now!

FREE TRIAL or TAKE THE TOUR